[go: up one dir, main page]

NO20065078L - Inhalation powder formulations containing enantiomerically pure beta agonists. - Google Patents

Inhalation powder formulations containing enantiomerically pure beta agonists.

Info

Publication number
NO20065078L
NO20065078L NO20065078A NO20065078A NO20065078L NO 20065078 L NO20065078 L NO 20065078L NO 20065078 A NO20065078 A NO 20065078A NO 20065078 A NO20065078 A NO 20065078A NO 20065078 L NO20065078 L NO 20065078L
Authority
NO
Norway
Prior art keywords
enantiomerically pure
powder formulations
formulations containing
beta agonists
inhalation powder
Prior art date
Application number
NO20065078A
Other languages
Norwegian (no)
Inventor
Michael Trunk
Jorg Schiewe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35058202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065078(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20065078L publication Critical patent/NO20065078L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse angår pulverformuleringer for inhalering inneholdende enantiomerisk rene forbindelser med den geneelle formel 1 hvor gruppene R1, R2, R3 og R4 kan ha betydningene angitt i kravene og i beskrivelsen, eventuelt i form av de farmasøytisk akseptable syreaddisjonssalter derav, samt eventuelt i kombinasjon med et farmasøytisk akseptabelt tilsetningsmiddel, fremgangsmåter for fremstilling av dem og anvendelse av dem som farmasøytiske preparater, spesielt som farmasøytiske preparater for behandling av respiratoriske lidelser.The present invention relates to powder formulations for inhalation containing enantiomerically pure compounds of the general formula 1 wherein the groups R1, R2, R3 and R4 may have the meanings set forth in the claims and in the specification, optionally in the form of the pharmaceutically acceptable acid addition salts thereof, and optionally in combination with a pharmaceutically acceptable additives, methods of preparing them and using them as pharmaceutical preparations, especially as pharmaceutical preparations for the treatment of respiratory disorders.

NO20065078A 2004-05-14 2006-11-03 Inhalation powder formulations containing enantiomerically pure beta agonists. NO20065078L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004024451A DE102004024451A1 (en) 2004-05-14 2004-05-14 Powder formulations for inhalation containing enantiomerically pure beta agonists
PCT/EP2005/005078 WO2005110359A1 (en) 2004-05-14 2005-05-11 Inhalation powder formulations containing enantiomerically pure beta-agonists

Publications (1)

Publication Number Publication Date
NO20065078L true NO20065078L (en) 2006-11-28

Family

ID=35058202

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065078A NO20065078L (en) 2004-05-14 2006-11-03 Inhalation powder formulations containing enantiomerically pure beta agonists.

Country Status (24)

Country Link
EP (1) EP1809236B1 (en)
JP (1) JP4891899B2 (en)
KR (1) KR101270449B1 (en)
CN (1) CN1984638A (en)
AR (1) AR048899A1 (en)
AU (1) AU2005244424B2 (en)
BR (1) BRPI0511136A (en)
CA (1) CA2565915C (en)
DE (1) DE102004024451A1 (en)
DK (1) DK1809236T3 (en)
EA (1) EA012582B1 (en)
ES (1) ES2401786T3 (en)
IL (1) IL179215A (en)
MX (1) MXPA06013221A (en)
MY (1) MY145838A (en)
NO (1) NO20065078L (en)
PE (1) PE20060239A1 (en)
PL (1) PL1809236T3 (en)
SG (1) SG152258A1 (en)
TW (1) TW200607508A (en)
UA (1) UA86807C2 (en)
UY (1) UY28896A1 (en)
WO (1) WO2005110359A1 (en)
ZA (1) ZA200607785B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004024452A1 (en) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol formulation for the inhalation of beta agonists
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
RU2442771C2 (en) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Derivants of bicyclo[2, 2, 1] hept-7-ylamine and their applications
CN101208316B (en) 2005-08-15 2012-05-09 贝林格尔·英格海姆国际有限公司 Method for preparing beta-mimetics
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010076553A1 (en) 2008-12-30 2010-07-08 Dr. Reddy's Laboratories Ltd Sulfonamide compounds for the treatment of respiratory disorders
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2014056840A1 (en) 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Beta-2-adrenoceptor agonist for the treatment of cough
JP2019536812A (en) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Nintedanib for use in methods of treating interstitial lung disease by co-administration with olodaterol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (en) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim NEW BENZO HETEROCYCLES
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE4318455A1 (en) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Capsule holder
NZ522677A (en) * 2000-04-27 2004-10-29 Boehringer Ingelheim Pharma Novel, slow-acting betamimetics, a method for their production and their use as medicaments
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
DE10141377A1 (en) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Scattering process for the production of powder formulations
DE10212264A1 (en) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Crystalline micronisate, process for its preparation and its use for the manufacture of a medicament
UA80123C2 (en) 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
DE10253282A1 (en) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treatment of chronic obstructive pulmonary disease, using new or known N-substituted 2-amino-1-(benz-(1,4)-oxazin-3-on-8-yl)-ethanol derivative beta-mimetic agents, suitable for once-daily administration

Also Published As

Publication number Publication date
TW200607508A (en) 2006-03-01
BRPI0511136A (en) 2007-11-27
DE102004024451A1 (en) 2005-12-22
MXPA06013221A (en) 2007-02-08
EP1809236A1 (en) 2007-07-25
KR101270449B1 (en) 2013-06-04
SG152258A1 (en) 2009-05-29
IL179215A0 (en) 2007-03-08
AU2005244424A1 (en) 2005-11-24
CN1984638A (en) 2007-06-20
JP2007537195A (en) 2007-12-20
UY28896A1 (en) 2005-12-30
ZA200607785B (en) 2008-07-30
AU2005244424B2 (en) 2010-12-23
UA86807C2 (en) 2009-05-25
JP4891899B2 (en) 2012-03-07
EA012582B1 (en) 2009-10-30
EP1809236B1 (en) 2012-12-26
AR048899A1 (en) 2006-06-07
EA200602016A1 (en) 2007-06-29
PE20060239A1 (en) 2006-03-27
IL179215A (en) 2011-04-28
WO2005110359A1 (en) 2005-11-24
CA2565915C (en) 2013-12-10
DK1809236T3 (en) 2013-02-11
KR20070016169A (en) 2007-02-07
PL1809236T3 (en) 2013-05-31
ES2401786T3 (en) 2013-04-24
MY145838A (en) 2012-04-30
CA2565915A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
MX340965B (en) Combinations for the treatment of diseases involving cell proliferation.
NO20065078L (en) Inhalation powder formulations containing enantiomerically pure beta agonists.
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
NO20061657L (en) Pyrol derivatives with antibacterial activity
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
NO20070837L (en) Pyrido-pyrido pyrimidine derivatives, their preparation and therapeutic application for the treatment of cancer.
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
NO20072089L (en) Benzimidazole derivatives, compositions containing them, their preparation and their use
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
UA84896C2 (en) Hydronopol derivatives as agonists on human orl1 receptors
TW200626553A (en) Novel compounds
NO20073176L (en) New drugs for the treatment of respiratory diseases
MXPA05013050A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof.
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
SE0302570D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
UA84300C2 (en) HEXA- AND OCTAHYDRO-PYRIDO[1,2-a]PYRAZINE DERIVATIVES WITH NK1 ANTAGONISTIC ACTIVITY
SE0302572D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
NO20063619L (en) Diarylmethylpiperazine derivatives, preparation and use thereof
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
DE602006009556D1 (en) CHINOLIN DERIVATIVES FOR THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED ILLNESSES
TW200740440A (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
NO20053805L (en) Diarylmethylindenepiperidine derivatives, processes for their preparation, and use thereof
MA28930B1 (en) INDOLIN-2-ONE PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
SE0400285D0 (en) Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application